Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Immuneering CorpIMRX · Entity 5884 | Director | June 11, 2026 | June 11, 2026 |
| Zentalis Pharmaceuticals, Inc.ZNTL · Entity 5772 | Chief Medical Officer | May 09, 2024 | May 09, 2024 |
| Zymeworks BC Inc.ZYME · Entity 12038 | Chief Medical Officer | March 10, 2021 | March 12, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Immuneering Corp
Report date June 11, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $4.12 · Expires 2036-06-11 | Direct | 33,350 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 33,350 · Balance 33,350 F1: The option vests and becomes exercisable in equal monthly installments over a one-year period commencing on July 11, 2026, and will be fully vested and exercisable on June 11, 2027, or the date of the 2027 annual meeting of stockholders, whichever comes first. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and becomes exercisable in equal monthly installments over a one-year period commencing on July 11, 2026, and will be fully vested and exercisable on June 11, 2027, or the date of the 2027 annual meeting of stockholders, whichever comes first.
Zentalis Pharmaceuticals, Inc.
Report date May 09, 2024 · Filed May 09, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 373,876 |
Reported balance
After 2024-05-09 transaction · row 1
1 source rowRow 1 · 2024-05-09 · Sale · Disposed 3,356 · Balance 373,876 F1: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person.
Zymeworks BC Inc.
Report date March 10, 2021 · Filed March 12, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 5,377 |
Ending reported balance
After 2021-03-10 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2021-03-10 · Exercise / conversion · Acquired 2,500 · Balance 6,425 F1: Represents common shares issued upon vesting of one third of the restricted stock units ("RSUs") granted on March 10, 2020. Row 2 · 2021-03-10 · Sale · Disposed 1,048 · Balance 5,377 F2: Represents common shares sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs. Pursuant to the terms of the applicable RSU grant agreement (the "Grant Agreement"), effective on the grant date of the RSUs, the Reporting Person irrevocably adopted a 10b5-1 plan pursuant to which the Reporting Person elected to sell shares to cover tax withholding obligations and other applicable fees in accordance with the terms of the Grant Agreement. F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.80 to $35.15, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 5,000 |
Reported balance
After 2021-03-10 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-03-10 · Exercise / conversion · Disposed 2,500 · Balance 5,000 F4: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. F5: The RSUs were granted on March 10, 2020 and vest in three equal annual instalments beginning on March 10, 2021. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 8,125 |
Reported balance
After 2021-03-10 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-03-10 · Grant · Acquired 8,125 · Balance 8,125 F4: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. F7: The RSUs vest in three equal annual installments beginning on March 10, 2022. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.82 · Expires 2031-03-09 | Direct | 48,750 |
Reported balance
After 2021-03-10 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-03-10 · Grant · Acquired 48,750 · Balance 48,750 F6: Stock options vest as follows: (i) 25% of underlying shares on first anniversary of grant date and (ii) remainder of underlying shares in 36 equal monthly installments on last day of month following first anniversary of grant date. |
| Common SharesSEC Table I · non-derivative | IndirectHeld by spouse | 2,000 |
Reported balance
Holding disclosure · report date 2021-03-10 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 2,000 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents common shares issued upon vesting of one third of the restricted stock units ("RSUs") granted on March 10, 2020.
F2: Represents common shares sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs. Pursuant to the terms of the applicable RSU grant agreement (the "Grant Agreement"), effective on the grant date of the RSUs, the Reporting Person irrevocably adopted a 10b5-1 plan pursuant to which the Reporting Person elected to sell shares to cover tax withholding obligations and other applicable fees in accordance with the terms of the Grant Agreement.
F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.80 to $35.15, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F4: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock.
F5: The RSUs were granted on March 10, 2020 and vest in three equal annual instalments beginning on March 10, 2021.
F6: Stock options vest as follows: (i) 25% of underlying shares on first anniversary of grant date and (ii) remainder of underlying shares in 36 equal monthly installments on last day of month following first anniversary of grant date.
F7: The RSUs vest in three equal annual installments beginning on March 10, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2026 Filed Jun 11, 2026 21:33 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 33,350 | $0.00 Strike: $4.12 | $0.00 |
DisclosureSEC source: 0001790340-26-000070 · wk-form4_1781213596.xml · derivative · entry 1 HAUSMAN DIANA · CIK 0001563992 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,350 Underlying: Class A Common Stock · 33,350 shares Expires 2036-06-11 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a one-year period commencing on July 11, 2026, and will be fully vested and exercisable on June 11, 2027, or the date of the 2027 annual meeting of stockholders, whichever comes first. Read SEC document |
| July 02, 2025 Filed Jul 7, 2025 12:59 UTC | Immuneering Corp IMRX · Entity 5884 | PurchaseClass A Common Stock | 3,000 | $3.62 | $10,873.50 |
DisclosureSEC source: 0001790340-25-000098 · wk-form4_1751893158.xml · nonDerivative · entry 2 HAUSMAN DIANA · CIK 0001563992 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By spouse Disclosed balance after: 3,000 Read SEC document |
| July 02, 2025 Filed Jul 7, 2025 12:59 UTC | Immuneering Corp IMRX · Entity 5884 | PurchaseClass A Common Stock | 2,500 | $3.60 | $8,989.00 |
DisclosureSEC source: 0001790340-25-000098 · wk-form4_1751893158.xml · nonDerivative · entry 1 HAUSMAN DIANA · CIK 0001563992 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,500 Read SEC document |
| June 13, 2025 Filed Jun 16, 2025 13:21 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 33,350 | $0.00 Strike: $1.90 | $0.00 |
DisclosureSEC source: 0001790340-25-000075 · wk-form4_1750080081.xml · derivative · entry 1 HAUSMAN DIANA · CIK 0001563992 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,350 Underlying: Class A Common Stock · 33,350 shares Expires 2035-06-13 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a one-year period commencing on July 13, 2025, and will be fully vested and exercisable on June 13, 2026, or the date of the 2026 annual meeting of stockholders, whichever comes first. Read SEC document |
| June 12, 2024 Filed Jun 13, 2024 20:16 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 33,350 | $0.00 Strike: $1.54 | $0.00 |
DisclosureSEC source: 0001628280-24-028052 · wk-form4_1718309804.xml · derivative · entry 1 HAUSMAN DIANA · CIK 0001563992 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,350 Underlying: Class A Common Stock · 33,350 shares Expires 2034-06-12 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a one-year period commencing on July 12, 2024, and will be fully vested and exercisable on June 12, 2025, or the date of the 2025 annual meeting of stockholders, whichever comes first. Read SEC document |
| May 09, 2024 Filed May 9, 2024 23:46 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 3,356 | $12.62 | $42,352.72 |
DisclosureSEC source: 0001725160-24-000111 · wk-form4_1715298409.xml · nonDerivative · entry 1 HAUSMAN DIANA · CIK 0001563992 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 373,876 F1 · kind: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person. Read SEC document |
| February 01, 2024 Filed Feb 6, 2024 00:16 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantStock Option (Right to Buy) · Derivative | 337,500 | $0.00 Strike: $11.69 | $0.00 |
DisclosureSEC source: 0001725160-24-000036 · wk-form4_1707178572.xml · derivative · entry 2 HAUSMAN DIANA · CIK 0001563992 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 337,500 Underlying: Common Stock · 337,500 shares Expires 2034-01-31 F2 · derivative.exercise_date: The options were granted to the Reporting Person in connection with Reporting Person's previously disclosed appointment as Chief Medical Officer, effective January 19, 2024. The options will vest over four years in equal monthly installments from the vesting commencement date of January 19, 2024 until the options are fully vested, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| February 01, 2024 Filed Feb 6, 2024 00:16 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantCommon Stock | 337,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001725160-24-000036 · wk-form4_1707178572.xml · nonDerivative · entry 1 HAUSMAN DIANA · CIK 0001563992 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 377,232 F1 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person in connection with Reporting Person's previously disclosed appointment as Chief Medical Officer, effective January 19, 2024. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in substantially equal annual installments over a four year period following the vesting commencement date of January 19, 2024, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| June 14, 2023 Filed Jun 15, 2023 20:39 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 17,500 | $0.00 Strike: $9.32 | $0.00 |
DisclosureSEC source: 0001790340-23-000037 · wk-form4_1686861571.xml · derivative · entry 1 HAUSMAN DIANA · CIK 0001563992 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,500 Underlying: Class A Common Stock · 17,500 shares Expires 2033-06-14 F1 · derivative.exercise_date: The option vests and becomes exercisable in substantially equal monthly installments over a one-year period with a vesting commencement date of June 14, 2023, and will be fully vested and exercisable on June 14, 2024, or the date of the 2024 annual meeting of stockholders, whichever comes first. Read SEC document |
| May 08, 2023 Filed May 10, 2023 11:13 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantCommon Stock | 39,732 | $0.00 | $0.00 |
DisclosureSEC source: 0001725160-23-000116 · wf-form4_168371718549282.xml · nonDerivative · entry 1 HAUSMAN DIANA · CIK 0001563992 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,732 F1 · shares: The restricted stock units ("RSUs") were granted by the Issuer pursuant to the Issuer's Non-Employee Director Compensation Program. One third of the RSUs will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date. Read SEC document |
| June 21, 2022 Filed Jun 23, 2022 20:56 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 6,185 | $0.00 Strike: $4.63 | $0.00 |
DisclosureSEC source: 0001415889-22-006896 · form4-06232022_010613.xml · derivative · entry 1 HAUSMAN DIANA · CIK 0001563992 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,185 Underlying: Class A Common Stock · 6,185 shares Expires 2032-06-20 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a one-year period commencing on July 21, 2022, and will be fully vested and exercisable on June 21, 2023, or the date of the 2023 annual meeting of stockholders, whichever comes first. Read SEC document |
| January 14, 2022 Filed Jan 18, 2022 13:21 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 25,200 | $13.00 Strike: $13.00 | $327,600.00 |
DisclosureSEC source: 0001415889-22-000586 · form4-01182022_050138.xml · derivative · entry 1 HAUSMAN DIANA · CIK 0001563992 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,200 Underlying: Class A Common Stock · 25,200 shares Expires 2032-01-13 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a three year period commencing on February 14, 2022, and will be fully vested and exercisable on January 14, 2025. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 20:00 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | GrantRestricted Stock Unit · Derivative | 8,125 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-011434 · doc4.xml · derivative · entry 6 HAUSMAN DIANA · CIK 0001563992 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,125 Underlying: Common Shares · 8,125 shares Expires not disclosed F4 · derivative.exercise_price: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. F7 · derivative.exercise_date: The RSUs vest in three equal annual installments beginning on March 10, 2022. F7 · derivative.expiration_date: The RSUs vest in three equal annual installments beginning on March 10, 2022. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 20:00 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | GrantStock Option (Right to Buy) · Derivative | 48,750 | $0.00 Strike: $34.82 | $0.00 |
DisclosureSEC source: 0000899243-21-011434 · doc4.xml · derivative · entry 5 HAUSMAN DIANA · CIK 0001563992 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,750 Underlying: Common Shares · 48,750 shares Expires 2031-03-09 F6 · derivative.exercise_date: Stock options vest as follows: (i) 25% of underlying shares on first anniversary of grant date and (ii) remainder of underlying shares in 36 equal monthly installments on last day of month following first anniversary of grant date. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 20:00 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | Exercise / conversionRestricted Stock Unit · Derivative | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-011434 · doc4.xml · derivative · entry 4 HAUSMAN DIANA · CIK 0001563992 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Shares · 2,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. F5 · derivative.exercise_date: The RSUs were granted on March 10, 2020 and vest in three equal annual instalments beginning on March 10, 2021. F5 · derivative.expiration_date: The RSUs were granted on March 10, 2020 and vest in three equal annual instalments beginning on March 10, 2021. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 20:00 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | SaleCommon Shares | 1,048 | $34.95 | $36,631.27 |
DisclosureSEC source: 0000899243-21-011434 · doc4.xml · nonDerivative · entry 2 HAUSMAN DIANA · CIK 0001563992 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,377 F2 · kind: Represents common shares sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs. Pursuant to the terms of the applicable RSU grant agreement (the "Grant Agreement"), effective on the grant date of the RSUs, the Reporting Person irrevocably adopted a 10b5-1 plan pursuant to which the Reporting Person elected to sell shares to cover tax withholding obligations and other applicable fees in accordance with the terms of the Grant Agreement. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.80 to $35.15, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 20:00 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | Exercise / conversionCommon Shares | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-011434 · doc4.xml · nonDerivative · entry 1 HAUSMAN DIANA · CIK 0001563992 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,425 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents common shares issued upon vesting of one third of the restricted stock units ("RSUs") granted on March 10, 2020. Read SEC document |
| January 07, 2021 Filed Jan 11, 2021 17:04 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | GrantCommon Shares | 207 | $30.92 | $6,400.44 |
DisclosureSEC source: 0000899243-21-001341 · doc4.xml · nonDerivative · entry 1 HAUSMAN DIANA · CIK 0001563992 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,925 F1 · kind: Shares purchased pursuant to the Issuer's Amended and Restated Employee Stock Purchase Plan (ESPP) for the ESPP purchase period July 1, 2020 through December 31, 2020. In accordance with the ESPP, these shares were purchased at a price equal to 85% the closing price of the Issuer's common shares on July 1, 2020. Read SEC document |
| December 04, 2020 Filed Dec 4, 2020 19:45 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,182 | $0.00 Strike: $11.84 | $0.00 |
DisclosureSEC source: 0000899243-20-032791 · doc4.xml · derivative · entry 6 HAUSMAN DIANA · CIK 0001563992 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,673 Underlying: Common Shares · 3,182 shares Expires 2028-03-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Pursuant to a 10b5-1 plan. F3 · derivative.exercise_date: Stock options vest as follows: (i) 25% of underlying shares on first anniversary of grant date and (ii) remainder of underlying shares in 36 equal monthly installments on last day of month following the first anniversary of grant date. The grant date was ten years before the listed expiration date. Read SEC document |
| December 04, 2020 Filed Dec 4, 2020 19:45 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,850 | $0.00 Strike: $9.82 | $0.00 |
DisclosureSEC source: 0000899243-20-032791 · doc4.xml · derivative · entry 5 HAUSMAN DIANA · CIK 0001563992 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,028 Underlying: Common Shares · 2,850 shares Expires 2027-06-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Pursuant to a 10b5-1 plan. F3 · derivative.exercise_date: Stock options vest as follows: (i) 25% of underlying shares on first anniversary of grant date and (ii) remainder of underlying shares in 36 equal monthly installments on last day of month following the first anniversary of grant date. The grant date was ten years before the listed expiration date. Read SEC document |
| December 04, 2020 Filed Dec 4, 2020 19:45 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | SaleCommon Shares | 6,032 | $55.12 | $332,476.00 |
DisclosureSEC source: 0000899243-20-032791 · doc4.xml · nonDerivative · entry 3 HAUSMAN DIANA · CIK 0001563992 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,718 F1 · kind: Pursuant to a 10b5-1 plan. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $55.00 to $55.38, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 4, 2020 at each separate price. Read SEC document |
| December 04, 2020 Filed Dec 4, 2020 19:45 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | Exercise / conversionCommon Shares | 3,182 | $11.84 | $37,674.88 |
DisclosureSEC source: 0000899243-20-032791 · doc4.xml · nonDerivative · entry 2 HAUSMAN DIANA · CIK 0001563992 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Pursuant to a 10b5-1 plan. Read SEC document |
| December 04, 2020 Filed Dec 4, 2020 19:45 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | Exercise / conversionCommon Shares | 2,850 | $9.82 | $27,987.00 |
DisclosureSEC source: 0000899243-20-032791 · doc4.xml · nonDerivative · entry 1 HAUSMAN DIANA · CIK 0001563992 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,568 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Pursuant to a 10b5-1 plan. Read SEC document |
| December 02, 2020 Filed Dec 3, 2020 19:54 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | Exercise / conversionStock Option (Right to Buy) · Derivative | 574 | $0.00 Strike: $11.84 | $0.00 |
DisclosureSEC source: 0000899243-20-032703 · doc4.xml · derivative · entry 11 HAUSMAN DIANA · CIK 0001563992 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,281 Underlying: Common Shares · 574 shares Expires 2028-03-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Pursuant to a 10b5-1 plan. F4 · derivative.exercise_date: Stock options vest as follows: (i) 25% of underlying shares on first anniversary of grant date and (ii) remainder of underlying shares in 36 equal monthly installments on last day of month following the first anniversary of grant date. The grant date was ten years before the listed expiration date. Read SEC document |
| December 02, 2020 Filed Dec 3, 2020 19:54 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | Exercise / conversionStock Option (Right to Buy) · Derivative | 127 | $0.00 Strike: $9.82 | $0.00 |
DisclosureSEC source: 0000899243-20-032703 · doc4.xml · derivative · entry 10 HAUSMAN DIANA · CIK 0001563992 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,751 Underlying: Common Shares · 127 shares Expires 2027-06-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Pursuant to a 10b5-1 plan. F4 · derivative.exercise_date: Stock options vest as follows: (i) 25% of underlying shares on first anniversary of grant date and (ii) remainder of underlying shares in 36 equal monthly installments on last day of month following the first anniversary of grant date. The grant date was ten years before the listed expiration date. Read SEC document |
| December 02, 2020 Filed Dec 3, 2020 19:54 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | SaleCommon Shares | 701 | $55.01 | $38,562.99 |
DisclosureSEC source: 0000899243-20-032703 · doc4.xml · nonDerivative · entry 6 HAUSMAN DIANA · CIK 0001563992 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,718 F1 · kind: Pursuant to a 10b5-1 plan. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $55.00 to $55.05, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 2, 2020 at each separate price. Read SEC document |
| December 02, 2020 Filed Dec 3, 2020 19:54 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | Exercise / conversionCommon Shares | 574 | $11.84 | $6,796.16 |
DisclosureSEC source: 0000899243-20-032703 · doc4.xml · nonDerivative · entry 5 HAUSMAN DIANA · CIK 0001563992 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,419 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Pursuant to a 10b5-1 plan. Read SEC document |
| December 02, 2020 Filed Dec 3, 2020 19:54 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | Exercise / conversionCommon Shares | 127 | $9.82 | $1,247.14 |
DisclosureSEC source: 0000899243-20-032703 · doc4.xml · nonDerivative · entry 4 HAUSMAN DIANA · CIK 0001563992 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,845 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Pursuant to a 10b5-1 plan. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 19:54 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,145 | $0.00 Strike: $11.84 | $0.00 |
DisclosureSEC source: 0000899243-20-032703 · doc4.xml · derivative · entry 9 HAUSMAN DIANA · CIK 0001563992 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,855 Underlying: Common Shares · 14,145 shares Expires 2028-03-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Pursuant to a 10b5-1 plan. F4 · derivative.exercise_date: Stock options vest as follows: (i) 25% of underlying shares on first anniversary of grant date and (ii) remainder of underlying shares in 36 equal monthly installments on last day of month following the first anniversary of grant date. The grant date was ten years before the listed expiration date. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 19:54 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,122 | $0.00 Strike: $9.82 | $0.00 |
DisclosureSEC source: 0000899243-20-032703 · doc4.xml · derivative · entry 8 HAUSMAN DIANA · CIK 0001563992 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,878 Underlying: Common Shares · 4,122 shares Expires 2027-06-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Pursuant to a 10b5-1 plan. F4 · derivative.exercise_date: Stock options vest as follows: (i) 25% of underlying shares on first anniversary of grant date and (ii) remainder of underlying shares in 36 equal monthly installments on last day of month following the first anniversary of grant date. The grant date was ten years before the listed expiration date. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 19:54 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | SaleCommon Shares | 18,267 | $55.19 | $1,008,239.76 |
DisclosureSEC source: 0000899243-20-032703 · doc4.xml · nonDerivative · entry 3 HAUSMAN DIANA · CIK 0001563992 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,718 F1 · kind: Pursuant to a 10b5-1 plan. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $55.00 to $55.67, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 1, 2020 at each separate price. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 19:54 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | Exercise / conversionCommon Shares | 14,145 | $11.84 | $167,476.80 |
DisclosureSEC source: 0000899243-20-032703 · doc4.xml · nonDerivative · entry 2 HAUSMAN DIANA · CIK 0001563992 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,985 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Pursuant to a 10b5-1 plan. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 19:54 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | Exercise / conversionCommon Shares | 4,122 | $9.82 | $40,478.04 |
DisclosureSEC source: 0000899243-20-032703 · doc4.xml · nonDerivative · entry 1 HAUSMAN DIANA · CIK 0001563992 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,840 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Pursuant to a 10b5-1 plan. Read SEC document |
| September 14, 2020 Filed Sep 16, 2020 17:03 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $11.84 | $0.00 |
DisclosureSEC source: 0001209191-20-050723 · doc4.xml · derivative · entry 10 HAUSMAN DIANA · CIK 0001563992 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Shares · 10,000 shares Expires 2028-03-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Pursuant to a 10b5-1 plan. F4 · derivative.exercise_date: Stock options vest as follows: (i) 25% of underlying shares on first anniversary of grant date and (ii) remainder of underlying shares in 36 equal monthly installments on last day of month following first anniversary of grant date. The grant date was ten years before the listed expiration date. Read SEC document |
| September 14, 2020 Filed Sep 16, 2020 17:03 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $9.82 | $0.00 |
DisclosureSEC source: 0001209191-20-050723 · doc4.xml · derivative · entry 9 HAUSMAN DIANA · CIK 0001563992 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Shares · 10,000 shares Expires 2027-06-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Pursuant to a 10b5-1 plan. F4 · derivative.exercise_date: Stock options vest as follows: (i) 25% of underlying shares on first anniversary of grant date and (ii) remainder of underlying shares in 36 equal monthly installments on last day of month following first anniversary of grant date. The grant date was ten years before the listed expiration date. Read SEC document |
| September 14, 2020 Filed Sep 16, 2020 17:03 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $17.15 | $0.00 |
DisclosureSEC source: 0001209191-20-050723 · doc4.xml · derivative · entry 8 HAUSMAN DIANA · CIK 0001563992 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,235 Underlying: Common Shares · 10,000 shares Expires 2027-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Based on an exchange rate of US$1.00 to CAD1.3175 as of September 14, 2020. F1 · kind: Pursuant to a 10b5-1 plan. F4 · derivative.exercise_date: Stock options vest as follows: (i) 25% of underlying shares on first anniversary of grant date and (ii) remainder of underlying shares in 36 equal monthly installments on last day of month following first anniversary of grant date. The grant date was ten years before the listed expiration date. Read SEC document |
| September 14, 2020 Filed Sep 16, 2020 17:03 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $15.74 | $0.00 |
DisclosureSEC source: 0001209191-20-050723 · doc4.xml · derivative · entry 7 HAUSMAN DIANA · CIK 0001563992 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,702 Underlying: Common Shares · 10,000 shares Expires 2026-11-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Based on an exchange rate of US$1.00 to CAD1.3175 as of September 14, 2020. F1 · kind: Pursuant to a 10b5-1 plan. F4 · derivative.exercise_date: Stock options vest as follows: (i) 25% of underlying shares on first anniversary of grant date and (ii) remainder of underlying shares in 36 equal monthly installments on last day of month following first anniversary of grant date. The grant date was ten years before the listed expiration date. Read SEC document |
| September 14, 2020 Filed Sep 16, 2020 17:03 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | SaleCommon Shares | 40,000 | $45.00 | $1,800,000.00 |
DisclosureSEC source: 0001209191-20-050723 · doc4.xml · nonDerivative · entry 5 HAUSMAN DIANA · CIK 0001563992 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,718 F1 · kind: Pursuant to a 10b5-1 plan. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.00 to $45.0550, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 14, 2020 at each separate price. Read SEC document |
| September 14, 2020 Filed Sep 16, 2020 17:03 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | Exercise / conversionCommon Shares | 10,000 | $11.84 | $118,400.00 |
DisclosureSEC source: 0001209191-20-050723 · doc4.xml · nonDerivative · entry 4 HAUSMAN DIANA · CIK 0001563992 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,718 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Pursuant to a 10b5-1 plan. Read SEC document |
| September 14, 2020 Filed Sep 16, 2020 17:03 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | Exercise / conversionCommon Shares | 10,000 | $9.82 | $98,200.00 |
DisclosureSEC source: 0001209191-20-050723 · doc4.xml · nonDerivative · entry 3 HAUSMAN DIANA · CIK 0001563992 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,718 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Pursuant to a 10b5-1 plan. Read SEC document |
| September 14, 2020 Filed Sep 16, 2020 17:03 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | Exercise / conversionCommon Shares | 10,000 | $17.15 | $171,500.00 |
DisclosureSEC source: 0001209191-20-050723 · doc4.xml · nonDerivative · entry 2 HAUSMAN DIANA · CIK 0001563992 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,718 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Pursuant to a 10b5-1 plan. F2 · price: Based on an exchange rate of US$1.00 to CAD1.3175 as of September 14, 2020. Read SEC document |
| September 14, 2020 Filed Sep 16, 2020 17:03 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | Exercise / conversionCommon Shares | 10,000 | $15.74 | $157,400.00 |
DisclosureSEC source: 0001209191-20-050723 · doc4.xml · nonDerivative · entry 1 HAUSMAN DIANA · CIK 0001563992 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,718 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Pursuant to a 10b5-1 plan. F2 · price: Based on an exchange rate of US$1.00 to CAD1.3175 as of September 14, 2020. Read SEC document |
| July 02, 2020 Filed Jul 6, 2020 20:01 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | GrantCommon Shares | 367 | $30.66 | $11,252.22 |
DisclosureSEC source: 0000950123-20-006723 · doc4.xml · nonDerivative · entry 1 HAUSMAN DIANA · CIK 0001563992 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,718 F1 · kind: Shares purchased pursuant to the Issuer's Amended and Restated Employee Stock Purchase Plan (ESPP) for the ESPP purchase period January 1, 2020 through June 30, 2020. In accordance with the ESPP, these shares were purchased at a price equal to 85% the closing price of the Issuer's common shares on June 30, 2020. Read SEC document |
| March 10, 2020 Filed Mar 11, 2020 20:31 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | GrantRestricted Stock Unit · Derivative | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-008004 · doc4.xml · derivative · entry 2 HAUSMAN DIANA · CIK 0001563992 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Shares · 7,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The restricted stock units vest in three equal annual installments beginning on March 10, 2021. F3 · derivative.expiration_date: The restricted stock units vest in three equal annual installments beginning on March 10, 2021. Read SEC document |
| March 10, 2020 Filed Mar 11, 2020 20:31 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | GrantStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $35.20 | $0.00 |
DisclosureSEC source: 0000899243-20-008004 · doc4.xml · derivative · entry 1 HAUSMAN DIANA · CIK 0001563992 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Shares · 45,000 shares Expires 2030-03-09 F1 · derivative.exercise_date: Stock options vest as follows: (i) 25% of underlying shares on first anniversary of grant date and (ii) remainder of underlying shares in 36 equal monthly installments on last day of month following first anniversary of grant date. Read SEC document |
| January 08, 2020 Filed Jan 9, 2020 16:05 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | GrantCommon Shares | 332 | $19.54 | $6,487.28 |
DisclosureSEC source: 0000899243-20-000878 · doc4.xml · nonDerivative · entry 1 HAUSMAN DIANA · CIK 0001563992 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,351 F1 · kind: Shares purchased pursuant to the issuer's Amended and Restated Employee Stock Purchase Plan (ESPP) for the ESPP purchase period July 1, 2019 through December 31, 2019. In accordance with the ESPP, these shares were purchased at a price equal to 85% the closing price of the issuer's common shares on July 1, 2019. Read SEC document |
| July 08, 2019 Filed Jul 10, 2019 16:56 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | GrantCommon Shares | 520 | $12.49 | $6,494.80 |
DisclosureSEC source: 0000899243-19-019437 · doc4.xml · nonDerivative · entry 1 HAUSMAN DIANA · CIK 0001563992 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,019 F1 · kind: Shares purchased pursuant to the issuer's Amended and Restated Employee Stock Purchase Plan (ESPP) for the ESPP purchase period January 1, 2019 through June 30, 2019. In accordance with the ESPP, these shares were purchased at a price equal to 85% the closing price of the issuer's common shares on January 2, 2019. Read SEC document |
| January 08, 2019 Filed Jan 10, 2019 17:55 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $15.53 | $0.00 |
DisclosureSEC source: 0000899243-19-000995 · doc4.xml · derivative · entry 2 HAUSMAN DIANA · CIK 0001563992 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Shares · 75,000 shares Expires 2029-01-07 F2 · derivative.exercise_date: Stock options vest as follows: (i) 25% of underlying shares on first anniversary of grant date and (ii) remainder of underlying shares in 36 equal monthly installments on last day of month following first anniversary of grant date. Read SEC document |
| January 08, 2019 Filed Jan 10, 2019 17:55 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | GrantCommon Shares | 499 | $12.48 | $6,227.52 |
DisclosureSEC source: 0000899243-19-000995 · doc4.xml · nonDerivative · entry 1 HAUSMAN DIANA · CIK 0001563992 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,499 F1 · kind: Shares purchased pursuant to the issuer's Amended and Restated Employee Stock Purchase Plan (ESPP) for the ESPP purchase period July 1, 2018 through December 31, 2018. In accordance with the ESPP, these shares were purchased at a price equal to 85% the closing price of the issuer's common shares on December 31, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.